Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.
Actively Recruiting
Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab combined with bevacizumab in people with advanced hepatocellular carcinoma HCC who cannot undergo curative or locoregional therapy. This Phase III, randomized, open-label, sponsor-blinded study includes a safety lead-in period before the main randomized treatment phase to assess tolerability. The study has three groups one receiving tremelimumab, rilvegostomig, and bevacizumab another receiving rilvegostomig and bevacizumab and a third group receiving atezolizumab and bevacizumab. All treatments are given by intravenous infusion. The initial safety lead-in is a single-arm phase focusing on the combination of rilvegostomig, bevacizumab, and tremelimumab, followed by a randomized period comparing the three treatment arms. Participants will be monitored for up to approximately six years to assess overall survival and other measures of treatment effect and safety. Assessments include evaluations of liver cancer progression, immune response, and any adverse events. The study involves regular clinical visits and evaluations to monitor health and treatment effects throughout the study duration.
Actively Recruiting
Researchers are evaluating the combination of sacituzumab tirumotecan and pembrolizumab compared to pembrolizumab alone in treating people with metastatic non-small cell lung cancer NSCLC who have high levels of PD-L1 expression at least 50%. The study aims to see whether adding sacituzumab tirumotecan improves overall survival compared to pembrolizumab alone. This is a phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. Sacituzumab tirumotecan is given by intravenous infusion on Days 1, 15, and 29 of each 6-week cycle, while pembrolizumab is administered by intravenous infusion on Day 1 of each 6-week cycle for up to 18 cycles. Supportive medications such as diphenhydramine, an H2 antagonist, acetaminophen, and dexamethasone are given around the first four infusions of sacituzumab tirumotecan to help manage infusion reactions. During the study, participants undergo assessments including overall survival, progression-free survival, response rates, and quality of life measured by validated questionnaires. Safety is monitored throughout the treatment period and beyond. The study tracks symptoms like cough, chest pain, and breathing difficulties, along with adverse events and treatment discontinuations. The total follow-up for outcomes may extend up to approximately 77 months, allowing for long-term monitoring of treatment effects and safety.
Actively Recruiting
Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.
1-10 of 16
1